- Home
- JRS vs PALI Comparison
JRS vs PALI Comparison
Compare JRS & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$1.86
Company Overview
Basic Information| Metric | JRS | PALI |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.9M | 240.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | JRS | PALI |
|---|---|---|
| Price | $7.90 | $1.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.29 |
| AVG Volume (30 Days) | 78.3K | ★ 3.9M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 8.87% | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $7.12 | $0.55 |
| 52 Week High | $8.38 | $2.64 |
Technical Indicators
Market Signals| Indicator | JRS | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 60.35 | 48.12 |
| Support Level | $7.56 | $1.57 |
| Resistance Level | $7.89 | $2.05 |
| Average True Range (ATR) | 0.16 | 0.18 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 90.52 | 54.41 |
Price Performance
Historical Comparison JRS
PALI
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.